Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZLHKJ)

• Drug Name: Adenine Drug Info
• Synonyms: ADE; ANE; Adenin; Adeninimine; Adenine [JAN]; Pedatisectine B; AD2; Vitamin B 4; Vitamin B4; ALBB-005925; Adenine (8CI); Adenine-ring; B 4, Vitamin; Leuco-4; Leucon (TN); Purine, 6; USAF CB-18; Vitamin-B4; Adenine (JAN/USP); Adenine-8-14C; 1,6-Dihydro-6-Imnopurine; 1,6-Dihydro-6-iminopurine; 1H-Purin-6-amine; 1H-Purin-6-amine (9CI); 1H-Purine, 6-amino; 2'-DEOXY-ADENOSINE-3'-5'-DIPHOSPHATE; 3,6-Dihydro-6-iminopurine; 4, Vitamin B; 6-Amino-1H-purine; 6-Amino-3H-purine; 6-Amino-7H-purine; 6-Amino-9H-purine; 6-Aminopurine; 7H-Purin-6-amine; 9H-Purin-6-amine

Indication

Disease Entry	ICD 11	Status	REF
Malnutrition	5B50-5B71	Approved	[1]

• Therapeutic Class: Dietary supplement
• Cross-matching ID:
  PubChem CID: 190
  ChEBI ID: CHEBI:16708
  CAS Number: CAS 73-24-5
  TTD Drug ID: DMZLHKJ
  VARIDT Drug ID: DR00126

Molecule-Related Drug Atlas

Drug(s) Targeting Human Deoxyribonucleic acid (hDNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[5]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[6]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[7]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[8]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[9]
Carboplatin	DMG281S	Adenocarcinoma	2D40	Approved	[10]
Busulfan	DMXYJ9C	Chronic myelogenous leukaemia	2A20.0	Approved	[11]
Procarbazine	DMIK367	Hodgkin lymphoma	2B30	Approved	[12]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[13]
Dacarbazine	DMNPZL4	Adenocarcinoma	2D40	Approved	[14]

Drug(s) Affected By Succinate dehydrogenase assembly factor 1, mitochondrial (SDHAF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[15]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[17]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[18]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[19]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[20]

Drug(s) Affected By Serine/threonine-protein kinase Sgk1 (SGK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[21]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[22]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[23]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[26]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[21]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[27]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[28]

Drug(s) Affected By E3 ubiquitin-protein ligase TRIM38 (TRIM38)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[29]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[30]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[31]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[32]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[33]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[34]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[35]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[15]

Drug(s) Affected By Torsin-1A (TOR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[38]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[39]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]

Drug(s) Affected By Ectoderm-neural cortex protein 1 (ENC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[41]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[31]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[43]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[44]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[46]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[47]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[48]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[49]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[50]
Selenium	DM25CGV	N. A.	N. A.	Approved	[51]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[52]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[53]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[52]

Drug(s) Affected By Plexin-B2 (PLXNB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[29]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[38]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[54]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[55]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[56]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[57]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[58]

Drug(s) Affected By Protein phosphatase 1D (PPM1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[59]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[60]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[61]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[62]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[63]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[34]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[64]

Drug(s) Affected By Regulator of G-protein signaling 16 (RGS16)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[65]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[66]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[67]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[69]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[71]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[72]

Drug(s) Affected By E3 ubiquitin-protein ligase RNF113A (RNF113A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[73]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[28]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]

Drug(s) Affected By DNA repair protein RAD51 homolog 3 (RAD51C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[74]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[75]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[76]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[77]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[77]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[76]

Drug(s) Affected By TP53-regulated inhibitor of apoptosis 1 (TRIAP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[28]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[15]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[64]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[64]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[79]

Drug(s) Affected By Dual specificity protein phosphatase 14 (DUSP14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[80]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[50]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[81]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[28]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[34]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]

Drug(s) Affected By Kinesin-like protein KIF20A (KIF20A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[59]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[65]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[82]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[75]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[77]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[77]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[15]

Drug(s) Affected By Myelin protein zero-like protein 1 (MPZL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[53]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[73]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[38]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[46]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]

Drug(s) Affected By G1/S-specific cyclin-E2 (CCNE2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[83]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[84]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[53]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[85]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[87]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[63]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[77]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[64]

Drug(s) Affected By Syndecan-1 (SDC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[88]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[38]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[89]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[90]

Drug(s) Affected By NADPH:adrenodoxin oxidoreductase, mitochondrial (FDXR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[60]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[71]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[38]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[91]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[91]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[92]

Drug(s) Affected By Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[93]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[94]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[95]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[38]

Drug(s) Affected By M-phase inducer phosphatase 1 (CDC25A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[83]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[97]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[98]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[75]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[99]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[100]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[101]

Drug(s) Affected By GTP cyclohydrolase 1 (GCH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[82]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[31]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[34]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[102]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]

Drug(s) Affected By Replication factor C subunit 1 (RFC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[73]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[103]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[104]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[55]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[56]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[87]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[105]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[106]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[107]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[108]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[60]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[109]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[110]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[111]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]

Drug(s) Affected By Tumor necrosis factor ligand superfamily member 9 (TNFSF9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[112]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[113]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[113]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[114]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[28]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]

Drug(s) Affected By RNA-binding protein 34 (RBM34)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[31]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[116]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[116]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[18]

Drug(s) Affected By LIM/homeobox protein Lhx2 (LHX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[31]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[32]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[117]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]

Drug(s) Affected By DNA mismatch repair protein Msh6 (MSH6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[83]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[65]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[66]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[71]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[38]

Drug(s) Affected By RecQ-like DNA helicase BLM (BLM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[83]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[65]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[75]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[77]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[77]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]

Drug(s) Affected By Ras-related protein Rap-2b (RAP2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[53]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[56]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[17]

Drug(s) Affected By Protein BTG1 (BTG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[118]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[27]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[119]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[120]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[118]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[71]

Drug(s) Affected By Protein BTG2 (BTG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[60]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[66]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[121]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[122]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[123]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[124]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[63]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[120]

Drug(s) Affected By Transcription factor E2F1 (E2F1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[125]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[126]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[127]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[128]
Selenium	DM25CGV	N. A.	N. A.	Approved	[29]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[129]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[130]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[75]

Drug(s) Affected By DNA-binding protein inhibitor ID-3 (ID3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[131]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[21]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[65]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[132]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[112]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[75]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[133]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[134]

Drug(s) Affected By Tripartite motif-containing protein 26 (TRIM26)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[124]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[39]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[135]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[65]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[55]

Drug(s) Affected By E3 ubiquitin-protein ligase TRIM32 (TRIM32)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[15]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[38]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[136]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[17]

Drug(s) Affected By Chromatin assembly factor 1 subunit A (CHAF1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[73]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[75]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[31]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[77]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[77]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[137]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[39]

Drug(s) Affected By Chromatin assembly factor 1 subunit B (CHAF1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[75]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[77]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[77]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]

Drug(s) Affected By DNA topoisomerase 3-alpha (TOP3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[34]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[103]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[39]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[18]
Torcetrapib	DMDHYM7	Hyperlipidaemia	5C80	Discontinued in Phase 2	[138]
Lithium chloride	DMHYLQ2	Discovery agent	N.A.	Investigative	[139]

Drug(s) Affected By Protein BTG3 (BTG3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[123]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[140]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[141]

Drug(s) Affected By Histone RNA hairpin-binding protein (SLBP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[142]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[143]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[75]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[34]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[144]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]

Drug(s) Affected By Neutral amino acid transporter B(0) (SLC1A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[64]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[64]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[38]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[64]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]

Drug(s) Affected By E3 ubiquitin-protein ligase RNF19B (RNF19B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[134]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[134]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[71]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[145]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[134]

Drug(s) Affected By Protein MCM10 homolog (MCM10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[83]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[65]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[146]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[77]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[77]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[147]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[148]

Drug(s) Affected By Partner and localizer of BRCA2 (PALB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[149]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[58]

Drug(s) Affected By E3 ubiquitin-protein ligase TRIM22 (TRIM22)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[31]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[150]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[71]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[151]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[152]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[39]

Drug(s) Affected By Leucine-rich repeat-containing protein 47 (LRRC47)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[153]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[38]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[39]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[58]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[29]

Drug(s) Affected By Protein tyrosine phosphatase type IVA 1 (PTP4A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[154]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[35]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[15]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[71]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[19]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[155]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[156]

Drug(s) Affected By Cytochrome c oxidase assembly factor 7 (COA7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[65]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[39]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]

Drug(s) Affected By Mitochondrial potassium channel (CCDC51)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[157]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[45]

Drug(s) Affected By Integrator complex subunit 15 (INTS15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[29]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[39]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[17]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[29]

Drug(s) Affected By Pleckstrin homology domain-containing family F member 1 (PLEKHF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[158]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[39]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[159]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[160]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[161]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[58]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[18]

Drug(s) Affected By Cell division control protein 6 homolog (CDC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[83]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[130]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[162]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[75]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[66]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[99]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[77]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[77]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]

Drug(s) Affected By Growth/differentiation factor 15 (GDF15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[60]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[158]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[162]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[163]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[164]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[164]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[165]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[154]

Drug(s) Affected By Protein orai-3 (ORAI3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[65]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[64]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[64]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[137]

Drug(s) Affected By Protein pelota homolog (PELO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[166]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[28]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[167]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[38]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]

Drug(s) Affected By TIMELESS-interacting protein (TIPIN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[31]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[168]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[169]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]

Drug(s) Affected By tRNA pseudouridine(38/39) synthase (PUS3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[65]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[28]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[39]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]

Drug(s) Affected By Transmembrane protein 185B (TMEM185B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[65]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[136]

Drug(s) Affected By Interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Indomethacin	DMSC4A7	Bursitis		Approved	[170]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[65]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[171]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[58]

Drug(s) Affected By GrpE protein homolog 1, mitochondrial (GRPEL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[172]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[94]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[28]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[38]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]

Drug(s) Affected By p53-induced death domain-containing protein 1 (PIDD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[173]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[77]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[77]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[69]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[64]

Drug(s) Affected By Fructose-2,6-bisphosphatase TIGAR (TIGAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[65]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[173]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[34]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[64]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[103]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[64]

Drug(s) Affected By DNA damage-inducible transcript 4 protein (DDIT4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[174]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[175]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[176]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[31]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[177]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[44]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[63]

Drug(s) Affected By Forkhead box protein J2 (FOXJ2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[58]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[73]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[142]

Drug(s) Affected By Homologous-pairing protein 2 homolog (PSMC3IP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[178]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[77]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[77]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[137]

Drug(s) Affected By Protein CLN8 (CLN8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[142]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[112]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[28]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[179]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[39]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[55]

Drug(s) Affected By rRNA methyltransferase 2, mitochondrial (MRM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[137]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[39]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]

Drug(s) Affected By Frizzled-1 (FZD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[124]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[28]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[35]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[4]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[180]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]

Drug(s) Affected By 5'-AMP-activated protein kinase subunit beta-1 (PRKAB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[64]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[64]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[71]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[181]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[4]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]

Drug(s) Affected By Pleckstrin homology-like domain family A member 3 (PHLDA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[28]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[15]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[64]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[71]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[64]

Drug(s) Affected By Sestrin-1 (SESN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[182]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[44]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[63]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[183]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[77]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[77]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[15]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[64]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Binder	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Adenine nucleotide translocator 3 (SLC25A6)	DTLMGFJ	ADT3_HUMAN	Substrate	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1)	OT1OG4QZ	AAKB1_HUMAN	Gene/Protein Processing	[4]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2)	OTIN6G20	CPT2_HUMAN	Gene/Protein Processing	[4]
Cell division control protein 6 homolog (CDC6)	OTX93FE7	CDC6_HUMAN	Gene/Protein Processing	[4]
Chromatin assembly factor 1 subunit A (CHAF1A)	OTXSSY4H	CAF1A_HUMAN	Gene/Protein Processing	[4]
Chromatin assembly factor 1 subunit B (CHAF1B)	OTOMK4KH	CAF1B_HUMAN	Gene/Protein Processing	[4]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Gene/Protein Processing	[4]
Cytochrome c oxidase assembly factor 7 (COA7)	OTRQJYL6	COA7_HUMAN	Gene/Protein Processing	[4]
DNA damage-inducible transcript 4 protein (DDIT4)	OTHY8SY4	DDIT4_HUMAN	Gene/Protein Processing	[4]
DNA mismatch repair protein Msh6 (MSH6)	OT46FP09	MSH6_HUMAN	Gene/Protein Processing	[4]
DNA repair protein complementing XP-C cells	OTB09PXO	XPC_HUMAN	Gene/Protein Processing	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4788).
• [2] Escherichia coli DNA adenine methyltransferase: intrasite processivity and substrate-induced dimerization and activation. Biochemistry. 2009 Aug 11;48(31):7399-410.
• [3] Adenine nucleotide (ADP/ATP) translocase 3 participates in the tumor necrosis factor induced apoptosis of MCF-7 cells. Mol Biol Cell. 2007 Nov;18(11):4681-9.
• [4] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [5] Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
• [6] Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
• [7] 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
• [8] Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
• [9] O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
• [10] Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
• [11] DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
• [12] Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
• [13] Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
• [14] Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
• [15] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [16] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [17] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [18] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [19] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [20] Gene expression changes in primary human nasal epithelial cells exposed to formaldehyde in vitro. Toxicol Lett. 2010 Oct 5;198(2):289-95.
• [21] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [22] A novel, integrated in vitro carcinogenicity test to identify genotoxic and non-genotoxic carcinogens using human lymphoblastoid cells. Arch Toxicol. 2018 Feb;92(2):935-951. doi: 10.1007/s00204-017-2102-y. Epub 2017 Nov 6.
• [23] A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
• [24] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [25] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [26] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [27] Gene expression profile of multiple myeloma cell line treated by arsenic trioxide. J Huazhong Univ Sci Technolog Med Sci. 2007 Dec;27(6):646-9. doi: 10.1007/s11596-007-0606-z.
• [28] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [29] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [30] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [31] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [32] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [33] Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood. 2005 Feb 1;105(3):1214-21. doi: 10.1182/blood-2004-03-1182. Epub 2004 Sep 28.
• [34] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [35] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [36] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [37] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [38] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [39] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [40] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [41] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [42] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [43] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [44] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [45] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [46] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [47] Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep. 2007 Sep;18(3):523-9.
• [48] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [49] Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
• [50] Novel functional view of the crocidolite asbestos-treated A549 human lung epithelial transcriptome reveals an intricate network of pathways with opposing functions. BMC Genomics. 2008 Aug 7;9:376.
• [51] Death receptor 5 regulation during selenium-mediated apoptosis in human prostate cancer cells. Cancer Biol Ther. 2002 May-Jun;1(3):287-90. doi: 10.4161/cbt.83.
• [52] Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80. doi: 10.1093/jnci/djh322.
• [53] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [54] Role of phenytoin in wound healing: microarray analysis of early transcriptional responses in human dermal fibroblasts. Biochem Biophys Res Commun. 2004 Feb 13;314(3):661-6. doi: 10.1016/j.bbrc.2003.12.146.
• [55] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [56] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [57] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [58] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [59] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [60] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [61] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [62] microRNA expression alteration after arsenic trioxide treatment in HepG-2 cells. J Gastroenterol Hepatol. 2011 Jan;26(1):186-93. doi: 10.1111/j.1440-1746.2010.06317.x.
• [63] In vitro effects of aldehydes present in tobacco smoke on gene expression in human lung alveolar epithelial cells. Toxicol In Vitro. 2013 Apr;27(3):1072-81.
• [64] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [65] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [66] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [67] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [68] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [69] Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
• [70] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [71] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [72] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [73] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [74] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [75] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [76] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [77] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [78] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [79] Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment. Mutat Res. 2008 Oct 30;656(1-2):1-7.
• [80] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [81] Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology. 2009 Feb 27;256(3):183-90. doi: 10.1016/j.tox.2008.11.016. Epub 2008 Nov 28.
• [82] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [83] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [84] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [85] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [86] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [87] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [88] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [89] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [90] The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol. 1998 Mar;100(4):637-46. doi: 10.1046/j.1365-2141.1998.00623.x.
• [91] Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
• [92] The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 2009 Sep 4;284(36):24306-19.
• [93] Activation of the constitutive androstane receptor by monophthalates. Chem Res Toxicol. 2016 Oct 17;29(10):1651-1661.
• [94] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [95] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [96] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [97] Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
• [98] A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011 Jan;120(1):121-7. doi: 10.1016/j.ygyno.2010.10.003. Epub 2010 Oct 29.
• [99] Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. J Cell Biochem. 2010 Dec 15;111(6):1546-55. doi: 10.1002/jcb.22886.
• [100] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [101] Vitamin D receptor as a master regulator of the c-MYC/MXD1 network. Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18827-32. doi: 10.1073/pnas.1210037109. Epub 2012 Oct 29.
• [102] The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009 Feb;41(2):178-186.
• [103] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [104] Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
• [105] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [106] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [107] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [108] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [109] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [110] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [111] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [112] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [113] Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
• [114] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [115] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [116] The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
• [117] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [118] Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003 Aug 15;73(13):1705-19. doi: 10.1016/s0024-3205(03)00515-0.
• [119] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [120] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [121] Role of DNA Repair Pathways in Response to Zidovudine-induced DNA Damage in Immortalized Human Liver THLE2 Cells. Int J Biomed Sci. 2013 Mar;9(1):18-25.
• [122] Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures. Biol Pharm Bull. 2018 May 1;41(5):722-732. doi: 10.1248/bpb.b17-00913. Epub 2018 Feb 14.
• [123] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [124] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [125] Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat Med. 2004 Jan;10(1):40-7. doi: 10.1038/nm969. Epub 2003 Dec 14.
• [126] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [127] Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol Cancer Res. 2010 Mar;8(3):343-52. doi: 10.1158/1541-7786.MCR-09-0395. Epub 2010 Mar 9.
• [128] Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res. 2006 Sep-Oct;26(5A):3387-91.
• [129] Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
• [130] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [131] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [132] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [133] Expression of the helix-loop-helix protein inhibitor of DNA binding-1 (ID-1) is activated by all-trans retinoic acid in normal human keratinocytes. Toxicol Appl Pharmacol. 2006 Aug 1;214(3):219-29. doi: 10.1016/j.taap.2005.12.015. Epub 2006 Feb 21.
• [134] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [135] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [136] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [137] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [138] Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach. BMC Syst Biol. 2012 Dec 10;6:152.
• [139] Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
• [140] Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
• [141] BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis. 2009 Apr;30(4):662-70. doi: 10.1093/carcin/bgp042. Epub 2009 Feb 12.
• [142] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [143] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [144] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [145] Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res. 2005 May 1;65(9):3837-45.
• [146] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [147] Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion. Toxicol In Vitro. 2009 Apr;23(3):486-99.
• [148] Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
• [149] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [150] Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008 Oct;7(10):1607-18.
• [151] Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
• [152] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [153] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [154] DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis. 2004 Jul;25(7):1293-8.
• [155] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [156] Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. J Appl Toxicol. 2023 Aug;43(8):1214-1224. doi: 10.1002/jat.4457. Epub 2023 Mar 11.
• [157] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [158] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [159] Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006 Dec 1;66(23):11187-93. doi: 10.1158/0008-5472.CAN-06-1274.
• [160] Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31. doi: 10.1289/ehp.10861.
• [161] Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol. 2013 May;169(1):167-78.
• [162] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [163] Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem. 2004 Feb 20;279(8):6883-92. doi: 10.1074/jbc.M305295200. Epub 2003 Dec 8.
• [164] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [165] Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. Br J Haematol. 2009 Jan;144(2):251-62. doi: 10.1111/j.1365-2141.2008.07441.x. Epub 2008 Nov 19.
• [166] The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma. Mol Cancer Ther. 2007 Apr;6(4):1300-9.
• [167] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [168] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [169] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [170] Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia. 2006 Sep;8(9):758-71.
• [171] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [172] Protein expression profiling identifies molecular targets of quercetin as a major dietary flavonoid in human colon cancer cells. Proteomics. 2004 Jul;4(7):2160-74.
• [173] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [174] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [175] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [176] Identification of troglitazone responsive genes: induction of RTP801 during troglitazone-induced apoptosis in Hep 3B cells. BMB Rep. 2010 Sep;43(9):599-603. doi: 10.5483/BMBRep.2010.43.9.599.
• [177] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [178] Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
• [179] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [180] The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry. 2009 Nov 3;48(43):10267-74. doi: 10.1021/bi9009677.
• [181] AMPK-dependent signaling modulates the suppression of invasion and migration by fenofibrate in CAL 27 oral cancer cells through NF-B pathway. Environ Toxicol. 2016 Jul;31(7):866-76. doi: 10.1002/tox.22097. Epub 2014 Dec 24.
• [182] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [183] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.